Endo Wields The Axe Again As It Eyes $95m Annual Savings
Two US Manufacturing Sites To Close; Other Measures Taken
Executive Summary
Hundreds more jobs are to go at Endo under further cost-cutting measures, including the closure of multiple sites serving the US-based player’s Generics business. Management discussed the issue on Endo’s third-quarter earnings call.
You may also be interested in...
Endo Buys Six Injectables Amid Shattering Decline In EBITDA Guidance
Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of generic competition to its lucrative Vasostrict injectable led the firm to disclose potentially catastrophic Q2 profitability guidance.
Endo’s Par Delivers On Nevakar Alliance With First Launch
Endo’s Par has announced the first launch under a longstanding US collaboration with 505(b)(2) specialist Nevakar, in the form of pre-mixed ephedrine sulfate injection in a ready-to-use 50mg/10ml single-use vial.
Strides Completes Acquisition Of Endo US Facility And ANDAs
Two months after announcing the deal, Strides Pharma Science has closed its acquisition of a US manufacturing site and basket of ANDAs from Endo, doubling the company’s burgeoning US business and providing much-needed cash to the US-based company.